

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 1/22/20

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2) VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2) Infringuinal revascularized PAD (2) Pediatric VTE (2)	Approved 10/19 Phase III Phase III Phase III	
	INVOKANA® (canagliflozin) apocritentan	Treatment of Diabetic Kidney Disease in adults with T2DM (2) Difficult to treat hypertension (2)	Approved 9/19 Phase III	Filed 7/19 Phase III
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis Crohn's Disease Pediatric Psoriasis	Filed 9/19 Phase IIB/III Phase III	Filed 10/19 Phase IIB/III Phase III
	SIMPONI® STELARA® (ustekinumab)	Pediatric Ulcerative Colitis Pediatric Psoriasis (6-11 year olds) Ulcerative Colitis Lupus	Phase III Filed 9/19 Approved 10/19 Phase III	Phase III Approved 1/20 Approved 9/19 Phase III
Infectious Diseases and Vaccines	Rilpivirine Long Acting nanosuspension for injection	HIV Infection	Complete Response 12/19	Filed 7/19
	pimodivir (JNJ-3872) VAC52150 VAC89220	Influenza A (2) Monovalent Ebola Virus Vaccine HIV Px Vaccine	Phase III Phase III Phase III	Phase III Filed 11/19 Phase III
	SPRAVATO™ (esketamine)	Treatment-resistant depression Major depressive disorder who have active suicidal ideation with intent	Approved 3/19 Filed 10/19	Approved 12/19 Filed 1/20
Neuroscience	ponesimod paliperidone palmitate 6 month long-acting injectable	Monotherapy for multiple sclerosis Treatment of Schizophrenia	Phase III Phase III	Phase III Phase III
	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006, CASSIOPEIA) (2) Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY3008, MAIA) (2) Relapsed Refractory MM 1+ prior lines w/PomDex (2) Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2) Amyloidosis (AMY 3001) (2) Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (MMY3012, COLUMBA) (2) Smoldering multiple myeloma (SMM3001) (2) Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2) Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Approved 9/19 Approved 6/19 Phase III Phase III Phase III Filed 7/19 Phase III Phase III	Approved 1/20 Approved 11/19 Phase III Phase III Phase III Filed 7/19 Phase III Phase III
Oncology	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2) Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2) Frontline Chronic Lymphocytic Leukemia in combination with Rituximab (Young and Fit) (ECOG 1912) (2) Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2) Frontline Chronic graft-versus-host-disease (cGVHD) (2) Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III Phase III Filed 11/19 Phase III Phase III Phase III	Phase III Phase III Filed 1/20 Phase III Phase III Phase III
	ERLEADA® (apalutamide)	Metastatic castrate sensitive prostate cancer (TITAN) Localized prostate cancer High risk prostate cancer (PROTEUS)	Approved 9/19 Phase III Phase III	Positive CHMP Opinion 12/19 Phase III Phase III
	apalutamide/ abiraterone acetate	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
	BALVERSA™ (erdafitinib)	Urothelial cancer (2)	Approved 4/19	Phase III
	niraparib (PARP inhibitor) niraparib / abiraterone acetate BCMA CAR-T	L3 Prostate cancer metastatic castration-resistant L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone Relapsed refractory multiple myeloma (2)	Phase IIB Phase III Phase II	Phase IIB Phase III Phase II
Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension	Phase III Phase III Complete Response 1/19	Phase III Phase III Submission Withdrawn 11/19
	UPTRAVI®	Pulmonary arterial hypertension IV Chronic thromboembolic pulmonary hypertension	Phase III Phase III	Phase III Phase III
	Macitentan w/tadalafil FDC	Pulmonary arterial hypertension	Phase III	Phase III

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; apocritentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.



Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of January 22, 2020

NMEs APPROVED 2019	NMEs IN REGISTRATION	NME PLANNED FILINGS 2020-2023*	
Oncology	Infectious Diseases & Vaccines	Oncology	Neuroscience
ERLEADA® (apalutamide) (EU) Non-metastatic prostate cancer BALVERSA™ (erdafitinib) (US) Urothelial cancer	Monovalent Ebola Vaccine (EU) Ebola virus Disease	Niraparib Metastatic castration-resistant prostate cancer (mCRPC) BCMA CAR-T Multiple Myeloma BALVERSA™ (erdafitinib) (EU) Urothelial cancer Lazertinib Non Small Cell Lung Cancer Cusatuzumab Acute myeloid leukemia JNJ-6372 (EGFR/cMET) Solid Tumor JNJ-7957 (BCMA/CD3), JNJ-7564 (GPCR5D/CD3) Multiple myeloma	Ponesimod Monotherapy for multiple sclerosis Seltorexant Adjunctive treatment for major depressive disorder with insomnia symptoms
			Infectious Diseases & Vaccines
			Pimodivir Influenza A RSV Sr vaccine RSV vaccine
			Cardiovascular & Metabolism
			CNGB3 and CNGA3 AAV Gene Therapy Achromatopsia RPGR AAV Gene Therapy X-linked retinitis pigmentosa Aprocitentan Difficult to treat hypertension
Neuroscience		Immunology	
SPRAVATO™ (Esketamine) Treatment resistant depression		JNJ-4500 Anti-NKG2D Crohn's disease	

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argencx; Lazertinib licensed from Yuhan Corporation; JNJ-4500 Anti-NKG2D licensed from Novo Nordisk; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; Seltorexant being developed in collaboration with Minerva Neurosciences; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (JNJ-6372, JNJ-7957, JNJ-7564); Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.

